Stockholders' Equity (Tables)

6 Months Ended

Jan. 31, 2015

Stockholders' Equity Note [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended January 31,				Six months ended January 31,
	2015		2014		2015		2014
Stock options	$	91	$	63	$	176	$	110
Restricted stock		14		46		27		102
	$	105	$	109	$	203	$	212

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended January 31,				Six months ended January 31,
	2015		2014		2015		2014
Cost of clinical laboratory services	$	2	$	2	$	3	$	4
Research and development		1		—		2		1
Selling, general and administrative		102		107		198		207
	$	105	$	109	$	203	$	212

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity during the six month period ended January 31, 2015:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2014		1,155,910		$	5.03
Awarded		383,873		$	3.57
Exercised		—		$	—
Cancelled or expired		(180,900	)	$	16.82
Outstanding at end of period		1,358,883		$	3.06		3.0 years	$	602
Exercisable at end of period		777,022		$	2.89	1.8 years		$	301

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the six months ended January 31, 2015 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2014		42,502		$	5.74
Awarded		3,000		$	5.62
Vested		(8,087	)	$	(1.86	)
Forfeited		(5,250	)	$	(3.31	)
Unvested at end of period		32,165		$	7.09